Dyne pivots on primary endpoint, delays filing for DM1 drug
Dyne Therapeutics met with the FDA to discuss what's needed for the accelerated approval of its myotonic dystrophy drug, and it settled on a different primary endpoint than expected. The company also
Dyne Therapeutics met with the FDA to discuss what's needed for the accelerated approval of its myotonic dystrophy drug, and it settled on a different primary endpoint than expected.
The company also
